The CDC advisory panel that helps set US vaccine policy said the use of RSV shots should be expanded to more adults, recommending the shot for all people 75 and older and for those aged 60 to 74 at risk of severe disease.
The agency’s Advisory Committee on Immunization Practices (ACIP) unanimously voted for the new guidance. Once the CDC officially signs off, it will broaden previous advice that said adults 60 and older should get vaccinated using “shared clinical decision-making” — meaning a conversation with a healthcare professional about their risks.
It’s a win — albeit a somewhat incremental one — for the three RSV vaccine manufacturers: GSK, Pfizer and Moderna. ACIP’s recommendations are critical for insurance coverage, with health plans required to cover vaccinations that fall within the guidance.
The committee declined to make a recommendation on vaccination for people aged 50 to 59, a group for whom…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
